Skip to the stories
Sunday, 22 November 2026
Saved

Next edition

5:31

Public Health

Infant RSV hospitalizations increased in second season after nirsevimab immunization

A two year study revealed that infant hospital admissions for respiratory syncytial virus were higher during the second season than during the initial protection period following nirsevimab immunization.

FTMQ Health, written by our newsroom0 views

Share

Infant hospital admissions for respiratory syncytial virus increased during the second season of life following nirsevimab immunization, Bioengineer.org reported. The findings come from a two year follow up study published in the journal Frontiers in Public Health. [1]

The research used a self-controlled case series methodology to evaluate hospitalization rates. In the adjusted self-controlled analysis, hospitalization rates during the second respiratory syncytial virus season were 7.99 times higher than during the initial effectiveness period of the antibody. The study reported a 95 percent confidence interval ranging from 5.80 to 11.02. [1]

Nirsevimab is a long acting monoclonal antibody created to protect infants against respiratory syncytial virus. Respiratory syncytial virus, also known as human orthopneumovirus, is a single-stranded RNA virus that causes infections of the human respiratory tract. [1][2]

Immunization functions by exposing the immune system to foreign molecules so the body learns to protect itself against infectious agents. The process relies on the adaptive immune system, including T cells and B cells, to develop immunological memory. [4]

Share

In short

  • Infant RSV hospitalization rates were 7.99 times higher in the second season following nirsevimab immunization than during the initial protection period.
  • The 95 percent confidence interval for the second season hospitalization rate increase spanned from 5.80 to 11.02.
  • Nirsevimab is a long-acting monoclonal antibody designed to protect infants against respiratory syncytial virus.
  • The two-year follow-up study was published in Frontiers in Public Health using a self-controlled case series design.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]RSV Hospitalizations Rose in Second Year Following Infant Nirsevimab ImmunizationBioengineer.org, 19h ago (the report this story comes from)

Background

  1. [2]Respiratory syncytial virus on Wikipedia
  2. [3]COVID-19 pandemic in the United States on Wikipedia
  3. [4]Immunization on Wikipedia
  4. [5]Royal College of Pharmacy ends sponsorship deal with Israeli drug firm FTMQ Health, 44d ago

Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Public Health

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.